ID   DFCI032
AC   CVCL_A763
SY   DFCI 032; DFCI.032; Dana-Farber Cancer Institute 032
DR   Cosmic; 1165895
DR   GEO; GSM794265
DR   Wikidata; Q54831034
RX   PubMed=18594010;
RX   PubMed=20679594;
RX   PubMed=26929325;
RX   PubMed=28196595;
RX   PubMed=29681454;
WW   https://tcpaportal.org/mclp/
CC   Part of: MD Anderson Cell Lines Project.
CC   HLA typing: A*02:01:01; B*44:02,51:01; C*05:01:01 (PubMed=26929325).
CC   Sequence variation: Gene fusion; HGNC; 427; ALK + HGNC; 1316; EML4; Name(s)=EML4-ALK (PubMed=18594010).
CC   Omics: Deep exome analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): PubMed=20679594
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 10,13
ST   D16S539: 11
ST   D5S818: 11,13
ST   D7S820: 10
ST   TH01: 9,9.3
ST   TPOX: 9
ST   vWA: 16,18
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 29-06-23; Version: 15
//
RX   PubMed=18594010; DOI=10.1158/1078-0432.CCR-08-0168;
RA   Koivunen J.P., Mermel C.H., Zejnullahu K., Murphy C., Lifshits E.,
RA   Holmes A.J., Choi H.G., Kim J., Chiang D., Thomas R., Lee J.,
RA   Richards W.G., Sugarbaker D.J., Ducko C.T., Lindeman N.I., Marcoux J.P.,
RA   Engelman J.A., Gray N.S., Lee C., Meyerson M.L., Janne P.A.;
RT   "EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung
RT   cancer.";
RL   Clin. Cancer Res. 14:4275-4283(2008).
//
RX   PubMed=20679594; DOI=10.1093/jnci/djq279;
RA   Gazdar A.F., Girard L., Lockwood W.W., Lam W.L., Minna J.D.;
RT   "Lung cancer cell lines as tools for biomedical discovery and
RT   research.";
RL   J. Natl. Cancer Inst. 102:1310-1321(2010).
//
RX   PubMed=26929325; DOI=10.1073/pnas.1521812113;
RA   Tripathi S.C., Peters H.L., Taguchi A., Katayama H., Wang H.,
RA   Momin A., Jolly M.K., Celiktas M., Rodriguez-Canales J., Liu H.,
RA   Behrens C., Wistuba I.I., Ben-Jacob E., Levine H., Molldrem J.J.,
RA   Hanash S.M., Ostrin E.J.;
RT   "Immunoproteasome deficiency is a feature of non-small cell lung
RT   cancer with a mesenchymal phenotype and is associated with a poor
RT   outcome.";
RL   Proc. Natl. Acad. Sci. U.S.A. 113:E1555-E1564(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=29681454; DOI=10.1016/j.cell.2018.03.028;
RA   McMillan E.A., Ryu M.-J., Diep C.H., Mendiratta S., Clemenceau J.R.,
RA   Vaden R.M., Kim J.-H., Motoyaji T., Covington K.R., Peyton M.,
RA   Huffman K., Wu X.-F., Girard L., Sung Y., Chen P.-H., Mallipeddi P.L.,
RA   Lee J.Y., Hanson J., Voruganti S., Yu Y., Park S., Sudderth J.,
RA   DeSevo C., Muzny D.M., Doddapaneni H., Gazdar A.F., Gibbs R.A.,
RA   Hwang T.H., Heymach J.V., Wistuba I.I., Coombes K.R., Williams N.S.,
RA   Wheeler D.A., MacMillan J.B., DeBerardinis R.J., Roth M.G.,
RA   Posner B.A., Minna J.D., Kim H.S., White M.A.;
RT   "Chemistry-first approach for nomination of personalized treatment in
RT   lung cancer.";
RL   Cell 173:864-878.e29(2018).
//